Back to Journals » ClinicoEconomics and Outcomes Research » Volume 9

Budget impact analysis of the simplification to atazanavir + ritonavir + lamivudine dual therapy of HIV-positive patients receiving atazanavir-based triple therapies in Italy starting from data of the Atlas-M trial [Corrigendum]

Authors Restelli U, Fabbiani M, Di Giambenedetto S, Nappi C, Croce D

Received 28 March 2017

Accepted for publication 28 March 2017

Published 19 April 2017 Volume 2017:9 Pages 231—232

DOI https://doi.org/10.2147/CEOR.S138166


Restelli U, Fabbiani M, Di Giambenedetto S, Nappi C, Croce D. Clinicoecon Outcomes Res. 2017;9:173–179.
  
On page 174, Methods section, 1st paragraph, the last sentence reads “The percentage of patients eligible for dual therapy (ATV+r+3TC) was derived from the Atlas-M trial at 48 weeks,20 in which patients were eligible to simplification if aged >17 years, receiving for at least 6 months ATV+r+2 NRTI, with “at least two HIV-RNA levels <50 copies/mL on two consecutive determinations at least 3 months apart,” for at least 6 months with a CD4 cell count >200 cells/mm3, no history of AIDS-related events in the year before enrollment.”. The correct sentence is “The percentage of patients eligible for dual therapy (ATV+r+3TC) was derived from the Atlas-M trial at 48 weeks,20 in which patients were eligible to simplification if aged ≥18 years, receiving for at least 6 months ATV+r+2 NRTI, with “at least two HIV-RNA levels <50 copies/mL on two consecutive determinations at least 3 months apart,” for at least 6 months with a CD4 cell count >200 cells/mm3, no history of AIDS-related events in the year before enrollment.”.

Read the original article


Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]